{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:08:21Z","timestamp":1791976101066,"version":"4.4.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1001\/jamaoncol.2018.0601","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T16:30:31Z","timestamp":1524760231000},"page":"814","source":"Crossref","is-referenced-by-count":32,"title":["Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib"],"prefix":"10.1001","volume":"4","author":[{"given":"Scott M.","family":"Schuetze","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bolejack","sequence":"additional","affiliation":[{"name":"Cancer Research and Biostatistics, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafydd G.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyaskumar","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Samuels","sequence":"additional","affiliation":[{"name":"Summit Cancer Centers, Post Falls, Idaho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Choy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"D\u2019Amato","sequence":"additional","affiliation":[{"name":"Georgia Cancer Specialists, Sandy Springs"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur P.","family":"Staddon","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen N.","family":"Ganjoo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford Cancer Institute, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren A.","family":"Chow","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Medical Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Rushing","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Forscher","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Priebat","sequence":"additional","affiliation":[{"name":"Medstar Washington Hospital Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Loeb","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Chugh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Okuno","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise K.","family":"Reinke","sequence":"additional","affiliation":[{"name":"Sarcoma Alliance for Research Through Collaboration, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"23","key":"coi180018r1","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"issue":"33","key":"coi180018r2","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","article-title":"Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi180018r3","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","article-title":"Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.","volume":"2","author":"Boikos","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"coi180018r4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9440","key":"coi180018r5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"coi180018r6","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamaoncol.2016.6728","article-title":"Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG Intergroup Trial S0033.","volume":"3","author":"Heinrich","year":"2017","journal-title":"JAMA Oncol"},{"issue":"29","key":"coi180018r7","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","article-title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.","volume":"24","author":"Heinrich","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9544","key":"coi180018r8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"33","key":"coi180018r9","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9863","key":"coi180018r10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"coi180018r11","doi-asserted-by":"publisher","first-page":"e65762","DOI":"10.1371\/journal.pone.0065762","article-title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.","volume":"8","author":"Hsueh","year":"2013","journal-title":"PLoS One"},{"issue":"18","key":"coi180018r12","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-08-0533","article-title":"Activity of dasatinib, a dual SRC\/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.","volume":"14","author":"Dewaele","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"coi180018r13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"coi180018r14","doi-asserted-by":"publisher","first-page":"e107613","DOI":"10.1371\/journal.pone.0107613","article-title":"Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.","volume":"9","author":"Sako","year":"2014","journal-title":"PLoS One"},{"issue":"20","key":"coi180018r15","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1002\/cncr.v117.20","article-title":"Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.","volume":"117","author":"Sawaki","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"coi180018r16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00280-011-1785-7","article-title":"Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.","volume":"69","author":"Cauchi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"27","key":"coi180018r17","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays.","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"issue":"6","key":"coi180018r18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/jso.23544","article-title":"Src activity is increased in gastrointestinal stromal tumors\u2014analysis of associations with clinical and other molecular tumor characteristics.","volume":"109","author":"Rotert","year":"2014","journal-title":"J Surg Oncol"},{"issue":"13","key":"coi180018r19","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi180018r20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cncr.v123.1","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.","volume":"123","author":"Schuetze","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"coi180018r21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/cncr.29858","article-title":"SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.","volume":"122","author":"Schuetze","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"coi180018r22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"issue":"282","key":"coi180018r23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-Estimation from Incomplete Observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"19","key":"coi180018r24","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","article-title":"Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.","volume":"15","author":"Demetri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"coi180018r25","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study.","volume":"5","author":"Wang","year":"2013","journal-title":"Clin Pharmacol"},{"issue":"11","key":"coi180018r26","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.","volume":"11","author":"Antonescu","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"coi180018r27","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/annonc\/mdr598","article-title":"Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.","volume":"23","author":"Reichardt","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"coi180018r28","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1245\/s10434-011-2120-6","article-title":"Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.","volume":"19","author":"Italiano","year":"2012","journal-title":"Ann Surg Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2678963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T09:48:19Z","timestamp":1720259299000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.0601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.0601","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}